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There has been signiﬁcant improvement in endovascular
repair (EVAR) of infrarenal aortic aneurysms over the last 22
years, since Juan Parodi ﬁrst reported on his historic cases.1
There are now several commercially available devices
approved for EVAR throughout the world. Utilization of this
technique for infrarenal abdominal aortic aneurysm (AAA)
repair varies worldwide, but has been shown to be up to
80% of all AAA repairs done in the USA.2,3 Despite its
widespread use in most patients, there are still subgroups in
which the beneﬁts of EVAR have not clearly been demon-
strated. The subgroup most often debated is the young
patient with good risk factors, which serves as the basis for
the following debate. While initially thought to be a rare
occurrence, this is an important controversy because in the
USA more than 5,000 patients a year between the age of 50
and 64 years undergo aneurysm repair.4 There are sub-
stantial reasons why young patients with good anatomic
characteristics and low comorbidities are very good candi-
dates for EVAR, and it should be offered to this subgroup.
PERI-OPERATIVE OUTCOMES AND EXPERTISE
There have been several large randomized controlled trials
comparing EVAR with open surgical repair (OSR). The EVAR-
1,5 DREAM,6 and OVER trials7 showed lower 30-day mor-
tality in patients undergoing EVAR when compared with
OSR. It should be noted that the ﬁrst two studies began
enrollment nearly a decade ago. Since that time, additional
device advances, technique improvement, and under-
standing in management of patients has occurred.
The ACE trial,8 a prospective trial of low-to-medium-risk
patients, showed equivocal peri-operative mortality be-
tween OSR and EVAR. One signiﬁcant criterion for
involvement in the ACE trial was expertise in both EVAR and
OSR. Based upon several articles,9e11 including the ACE trial
manuscript, this is generally deﬁned as >30 cases/year.
Currently, most vascular specialists outside of major aortic
centers rarely deal with this number of cases.12 It therefore
calls into question the applicability of these outcomes to
low-volume centers. Most practising physicians will only see
a few young patients a year afﬂicted with aneurysmal dis-
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results of the ACE trial are only valid when comparing
outcomes at large aortic centers where more than 30 cases
per year are seen. This is further supported by the fact that
none of the aforementioned EVAR trials showed a statistical
difference in mid-to-long-term all-cause mortality rates
between EVAR and OSR.7,8,13,14 Thus, it is beneﬁcial and
logical for the practising physician in low-volume centers to
perform the procedure with which he/she is most familiar.
In almost all situations, based upon today’s training and
experience paradigm, that would be EVAR.12
Medical therapy has also improved outcomes for EVAR. A
recent study showed an increased rate of sac regression
after EVAR in patients who were on statin therapy.15 Other
studies have demonstrated a decrease in all-cause mortality
with improved medical management, including statin ther-
apy, over the last decade.16 This suggests that some of the
outcome and mortality data from the trials of a decade ago
may need to be reinterpreted if the patients were not all on
optimal medical therapy. Other medications, such as doxy-
cycline, have also shown promise in improving outcomes
following EVAR.17 As the importance of medical manage-
ment of aneurysm patients becomes more widely known,
durability of repair in patients with EVAR will likely further
improve and become inconsequential in choosing the best
method of repair.
SECONDARY INTERVENTION RATES
Although there is a higher secondary re-intervention rate
for EVAR than OSR, accurate data collection is difﬁcult.
Most EVAR interventions are typically managed by endo-
vascular means. Patients who undergo OSR typically have
more open surgical-related complications, such as bowel
obstructions and hernias, which lead to in-patient hospi-
talization.18 Additionally, there seems to be a decrease in
secondary interventions from EVAR as experience grows,
advanced devices become available,19 and patient selection
improves. Secondary intervention rates as low as 7.4% have
been achieved.20 This is especially true for open conversion
rates, which have now been reported to be anywhere from
1.6% to 2.6%.21,22 Recent data from the UK reveal that
younger patients treated with EVAR may have similar rates
of secondary interventions when compared with OSR if
evaluated after several years.23
IMPACT OF PATIENT SELECTION
When considering the risk factors for a patient there are
physiologic-, anatomic-, and patient-speciﬁc risk factors.
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comes for EVAR. Implantation of an endoprosthesis into a
pre-aneurysmal neck or outside the instructions for use
(IFU) does not convey the same protection against rupture
and long-term outcome compared with published clinical
trial results. To be ideal candidates, patients should have
appropriate anatomical criteria for the speciﬁc endograft.
However, a large number of endografts inserted over the
last decade have been outside their deﬁned IFU. Analysis of
a large cohort of these patients has shown an alarming rate
of aneurysm sac enlargement, a high percentage of Type I
endoleaks, and an increase in all-cause mortality.24,25 Pa-
tients with anatomy within the IFU have lower re-
intervention rates.24 As more advanced devices in the
USA have not generally been available until recently, many
patients were treated outside their IFU. While in most in-
stances the intra-operative angiogram reveals sufﬁcient
aneurysmal exclusion, it is not until subsequent follow-up
surveillance that many problems are identiﬁed.26
One of the most important aspects of EVAR is the crucial
importance of follow-up evaluation. Young patients who are
not willing to commit to long-term follow-up are not good
risk patients for EVAR. Although the risk of postoperative
migration and endoleak is small, it still exists. Patients who
do follow-up on a regular basis should be less likely to
experience ruptures from undiagnosed type I or type III
endoleaks.
PATIENT PREFERENCE
To date, no clinical trial has demonstrated a detriment to
the patient when performing EVAR with respect to long-
term mortality. Additionally, most studies demonstrate a
distinct advantage of EVAR during the initial years after
repair. It is these two facts that drive most patients in their
decision. Given the choice, the majority of patients will
invariably choose EVAR over OSR. Several studies have
demonstrated that patients focus on the lower peri-
operative morbidity and mortality, and the shorter hospi-
tal stay with EVAR, even after weighing up the risk of higher
future secondary interventions.27e29 This also holds true for
younger patients, as they may still be employed and want
to return to work as soon as possible to provide for their
families. This increased patient productivity may help
reduce the overall economic impact of EVAR compared to
OSR, and should be considered when comparing these
different techniques.
COSTS
While cost comparative analyses between OSR and EVAR
have been attempted, it is difﬁcult to determine the eco-
nomic impact unless loss of productivity and other factors
are included in the analysis. Many older studies have stated
that EVAR is less cost-effective than OSR based on exami-
nation of device and hospital charges.30 However, a recent
publication from the OVER trial showed that EVAR cost less
than OSR in the peri-operative period.7 When examining
the initial 2-year postoperative period, there was nodifference in cost. The outcome of this analysis is also
constantly changing as supply and demand, as well as
hospital costs, change depending on the economic
situation.7
Additional costs are incurred during the follow-up period
as axial imaging studies are used to assess the effectiveness
of EVAR. There has been some concern that computed to-
mography (CT) scans may also increase the risk of induced
malignancy; however, most patients with aneurysmal dis-
ease, even if they are young, would rarely live long enough
to be exposed to this increased risk. As better knowledge of
endograft behaviors and factors that affect endoleak com-
plications are identiﬁed, alterations in follow-up have
occurred. Many centers have altered the number of CT
scans acquired for surveillance, as minimum beneﬁt is
added if an initial postoperative CT scan is found to be
normal.26 Institutions have also begun using a combination
of an X-ray and color duplex for postoperative evaluation,
further decreasing the costs after implantation.31,32
LIFE EXPECTANCY OF YOUNG PATIENTS WITH ANEURYSMS
A recently published article from the Nottingham group
looked at midterm survival in young patients treated with
EVAR and OSR.23 When analyzing patients treated at their
institution since 1995, nearly 40% of patients who were
treated with either OSR or EVAR died within 6 years of
surgery. The overwhelming majority of these patients did
not die from aneurysmal disease. In patients who were
treated with commercially available endografts, there was a
trend towards improved long term survival versus earlier
custom-made endografts (hazard ratio [HR] ¼ 2.9, 95%
conﬁdence interval (CI) ¼ 0.9e10.0; p ¼ .08) and OSR
(HR ¼ 3.1, 95% CI ¼ 0.9e10.3; p ¼ .07); however, this was
not statistically signiﬁcant.23 Patients with aneurysmal
aortas may not have the same life expectancy as patients in
the general population, and this may be a risk factor for
early mortality.
CONCLUSION
In young, motivated patients with good anatomic and
physiologic risk factors EVAR is as good as, if not better
than, OSR when early mortality is factored into the equa-
tion. Open surgical outcomes are particularly dependent
upon the surgeon’s experience, which has become
extremely limited in recent years. There are potential risks
of future secondary interventions with EVAR; however, the
majority of these are also repaired endovascularly and the
chance of needing an open surgical revision is extremely
low. The cost of EVAR and OSR are becoming comparable,
especially when societal impact is considered, as hospital
costs increase, graft costs decline with competition, and
alternative postoperative surveillance occurs. As medical
management, operator expertise, and endograft technology
improves, the long-term outcomes of endovascular therapy
should also continue to improve. Young patients with an-
eurysms may also not have the same long-term survival as
the general population, and may beneﬁt from a procedure
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in young, good risk patients the long-term mortality in EVAR
and OSR is equivocal. However, there tends to be less
perioperative mortality in EVAR, especially if the center’s
open surgical volume is limited. Therefore, only in centers of
excellence should both OSR and EVAR be offered to all
young, good risk patients to allow the patients to decide. In
almost all cases they will choose EVAR. In all low-volume
practices, EVAR should be preferentially offered.REFERENCES
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